Vitamin D and cardiovascular disease: A novel agent for reducing cardiovascular risk?

Current Vascular Pharmacology

Volumn 8, Issue 5, 2010, Pages 720-730

  Anagnostis, Panagiotis ^a   Athyros, Vasilios G ^b   Adamidou, Fotini ^a   Florentin, Matilda ^c   Karagiannis, Asterios ^b  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes mellitus; Hypertension; Metabolic syndrome; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; ATORVASTATIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VITAMIN D;

ADDISON DISEASE; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BONE DENSITY; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC POLYMORPHISM; GRAVES DISEASE; HASHIMOTO DISEASE; HEART DEATH; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIGHT EXPOSURE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; ADULT; BLOOD; CHILD; DIET SUPPLEMENTATION; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHILD; DIETARY SUPPLEMENTS; HUMANS; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77954805716     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016110792006978     Document Type: Review

References (140)

1. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros. VG, Mikhailidis DP. Atherosclerosis and osteoporosis: agedependent. degenerative processes or related entities? Osteoporos. Int 2009; 20: 197-207.
2. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and. risk of cardiovascular disease. Circulation 2008; 117: 503-11.
3. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D. deficiency an important, common, and easily treatable cardiovascular. risk factor? J Am Coll Cardiol 2008: 52: 1949-56.
4. Holick MF, Vitamin D, Engl J Med 2007; 357: 266-.81.
5. Hewison M, Burke F, Evans KN, et al. Extra-renal 25-. hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007; 103: 316-21.
6. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin. D receptor ligands. Endocr Rev 2005; 26: 662-87.
7. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T,. Dawson-Hughes B. Estimation of optimal serum concentrations of. 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006; 84: 18-28.
8. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158: 531-7.
9. Gaugris S, Heaney RP, Boonen S, Kurth H, Bentkover JD, Sen SS. Vitamin D inadequacy among post-menopausal women: a systematic. review. QJM 2005; 98: 667-76.
10. [10] Holick MF, Siris ES, Binkley N., Prevalence of Vitamin D. inadequacy among postmenopausal North American women receiving. osteoporosis therapy. J Clin Endocrinol Metab 2005; 90:. 3215-24.
11. Papapetrou PD, Triantaphyllopoulou M, Karga H, et al. Vitamin D. deficiency in the elderly in Athens, Greece. J Bone Miner Metab. 2007; 25: 198-203.
12. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of. calcium or calcium in combination with vitamin D supplementation. to prevent fractures and bone loss in people aged 50 years and. older: a meta-analysis. Lancet 2007; 370: 657-66.
13. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall. prevention with supplemental and active forms of vitamin D: a. meta-analysis of randomised controlled trials. BMJ 2009; 339:. b3692.
14. Kulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D:. an evidence-based review. J Am Board Fam Med 2009; 22: 698-. 706.
15. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D. levels and the risk of mortality in the general population. Arch Intern. Med 2008; 168: 1629-37.
16. Fleck A. Latitude and ischaemic heart disease. Lancet 1989; 1: 613.
17. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin. D deficiency is independently associated with cardiovascular disease. in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009; 205: 255-60.
18. [18] Kilkkinen A, Knekt P, Aro A., Vitamin D status and the risk. of cardiovascular disease death. Am J Epidemiol 2009; 170: 1032-9.
19. Chonchol M, Cigolini M, Targher G., Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2. diabetic patients with mild kidney dysfunction. Nephrol Dial. Transplant 2008; 23: 269-74.
20. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of. low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008; 168: 1340-9.
21. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective. study of serum 25-hydroxyvitamin D level, cardiovascular disease. mortality, and all-cause mortality in older U.S. adults. J Am Geriatr. Soc 2009; 57: 1595-603.
22. Pilz S, Dobnig H, Nijpels G, et al. Vitamin D and mortality in older. men and women. Clin Endocrinol (Oxf) 2009; 71: 666-72.
23. Wang AY, Lam CW, Sanderson JE, et al. Serum 25-. hydroxyvitamin D status and cardiovascular outcomes in chronic. peritoneal dialysis patients: a 3-y prospective cohort study. Am J. Clin Nutr 2008; 87: 1631-8.
24. Lund B, Badskjaer J, Lund B, Soerensen OH. Vitamin D and. ischaemic heart disease. Horm Metab Res 1978; 10: 553-6.
25. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial. infarction is inversely associated with plasma 25-. hydroxyvitamin D3 levels: a community based study. Int J Epidemiol. 1990; 19: 559-63.
26. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ., Prevalence. of hypovitaminosis D in cardiovascular diseases (from the National. Health and Nutrition Examination Survey 2001 to 2004). Am J. Cardiol 2008; 102: 1540-4.
27. Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher. G. Serum 25-hydroxyvitamin D3 concentrations and prevalence. of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722-4.
28. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin. D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168: 1174-80.
29. Gong G, Stern HS, Cheng SC, et al. The association of bone mineral. density with vitamin D receptor gene polymorphisms. Osteoporos. Int 1999; 9: 55-64.
30. Van Schooten FJ, Hirvonen A, Maas LM. Putative susceptibility. markers of coronary artery disease: association between VDR. genotype, smoking, and aromatic DNA adduct levels in human. right atrial tissue. FASEB J 1998; 12: 1409-17.
31. Ortlepp JR, von Korff A, Hanrath P, Zerres K, Hoffmann R. Vitamin. D receptor gene polymorphism BsmI is not associated with the. prevalence and severity of CAD in a large-scale angiographic cohort. of 3441 patients. Eur J Clin Invest 2003; 33: 106-9.
32. [32] Xiang W, Kong J, Chen S., Cardiac hypertrophy in vitamin D. receptor knockout mice: role of the systemic and cardiac reninangiotensin. systems. Am J Physiol Endocrinol Metab 2005; 288:125-32.
33. [33] Lemmilä S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A., Effect of intravenous calcitriol on cardiac systolic and diastolic. function in patients on hemodialysis. Am J Nephrol 1998; 18: 404-410.
34. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D insufficiency. in congestive heart failure: why and what to do about it? Heart Fail. Rev 2006; 11: 25-33.
35. Pilz S, März W, Wellnitz B, et al. Association of vitamin D deficiency. with heart failure and sudden cardiac death in a large crosssectional. study of patients referred for coronary angiography. J Clin. Endocrinol Metab 2008; 93: 3927-35.
36. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer. R, Stehle P. Low vitamin D status: a contributing factor in the. pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;. 41: 105-12.
37. Rubattu S, Sciarretta S, Valenti V, Stazione R, Volpe M. Natriuretic. peptides: an udate on bioactivity, potential therapeutic use,. and implication in cardiovascular diseases. Am J Hypertens 2008;. 21: 733-41.
38. Zittermann A, Schleithoff SS, Götting C, et al. Poor outcome in. end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008; 10: 321-7.
39. Poole KE, Loveridge N, Barker PJ, et al. Reduced vitamin D in. acute stroke. Stroke 2006; 37: 243-5.
40. Marniemi J, Alanen E, Impivaara O, et al. Dietary and serum vitamins. and minerals as predictors of myocardial infarction and stroke. in elderly subjects. Nutr Metab Cardiovasc Dis 2005; 15: 188-97.
41. Pilz S, Dobnig H, Fischer JE, et al. Low vitamin d levels predict. stroke in patients referred to coronary angiography. Stroke 2008;. 39: 2611-3.
42. [42] Fahrleitner-Pammer A, Obernosterer A, Pilger E., Hypovitaminosis. D, impaired bone turnover and low bone mass are common. in patients with peripheral arterial disease. Osteoporos Int 2005; 16:319-24.
43. Fahrleitner A, Dobnig H, Obernosterer A, et al. Vitamin D deficiency. and secondary hyperparathyroidism are common complications. in patients with peripheral arterial disease. J Gen Intern Med. 2002; 17: 663-9.
44. Melamed ML, Muntner P, Michos ED, et al. Serum 25-. hydroxyvitamin D levels and the prevalence of peripheral arterial. disease: results from NHANES 2001 to 2004. Arterioscler Thromb. Vasc Biol 2008; 28: 1179-85.
45. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-. dihydroxyvitamin D(3) is a negative endocrine regulator of the. rennin-angiotensin system. J Clin Invest 2002; 110: 229-38.
46. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart. size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-4.
47. Burgess ED, Hawkins RG, Watanabe M. Interaction of 1,25-. dihydroxyvitamin D and plasma renin activity in high renin essential. hypertension. Am J Hypertens 1990; 3: 903-5.
48. Anagnostis P, Karagiannis A, Tziomalos K, Athyros VG, Mikhailidis DP., Endocrine hypertension: diagnosis and management. of a complex clinical entity. Curr Vasc Pharm 2010 (in press).
49. Lind L, Wengle B, Wide L, Sörensen OH, Ljunghall S. Hypertension. in primary hyperparathyroidism-reduction of blood pressure. by long-term treatment with vitamin D (alphacalcidol). A doubleblind,. placebo-controlled study. Am J Hypertens 1988; 1: 397-402.
50. Rostand SG. Ultraviolet light may contribute to geographic and. racial blood pressure differences. Hypertension 1997; 30: 150-6.
51. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 1998; 352: 709-10.
52. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal. vitamin D status attenuates the age-associated increase in systolic. blood pressure in white Americans: results from the third National. Health and Nutrition Examination Survey. Am J Clin Nutr. 2008; 87: 136-41.
53. Lind L, Hänni A, Lithell H, Hvarfner A, Sörensen OH, Ljunghall. S. Vitamin D is related to blood pressure and other cardiovascular. risk factors in middle-aged men. Am J Hypertens 1995; 8: 894-901.
54. Reis JP, von Mühlen D, Miller ER, Michos ED, Appel LJ. Vitamin D status and cardiometabolic risk factors in the United. States adolescent population. Pediatrics 2009 Aug 3. [Epub ahead. of print].
55. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D. levels and risk of incident hypertension among young women. Hypertension. 2008; 52: 828-32.
56. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-. hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063-9.
57. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxycholecalciferol concentration in newly detected. hypertension. Am J Hypertens 1995; 8: 429-32.
58. Scragg R, Holdaway I, Jackson R, Lim T. Plasma 25-. hydroxyvitamin D3 and its relation to physical activity and other. heart disease risk factors in the general population. Ann Epidemiol. 1992; 2: 697-703.
59. [59] Snijder MB, Lips P, Seidell JC., Vitamin D status and parathyroid. hormone levels in relation to blood pressure: a populationbased. study in older men and women. J Intern Med 2007; 261: 558-65.
60. Cade C, Norman AW. Vitamin D3 improves impaired glucose. tolerance and insulin secretion in the vitamin D-deficient rat in. vivo. Endocrinology 1986; 119: 84-90.
61. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D. deficiency inhibits pancreatic secretion of insulin. Science 1980;. 209: 823-5.
62. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin. D receptor. FASEB J 2003; 17: 509-11.
63. Mathieu C, Van Etten E, Gysemans C, et al. In vitro and in vivo. analysis of the immune system of vitamin D receptor knockout. mice. J Bone Miner Res 2001; 16: 2057-65.
64. [64] Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose. tolerance and diabetes mellitus. Diabetes Res Clin Pract 1995; 27:. 181-8.
65. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated. with insulin resistance and beta cell dysfunction. Am J Clin. Nutr 2004; 79: 820-5.
66. Mattila C, Knekt P, Männistö S, et al. Serum 25-hydroxyvitamin D. concentration and subsequent risk of type 2 diabetes. Diabetes Care. 2007; 30: 2569-70.
67. Scragg R, Sowers M, Bell C; Third National Health and Nutrition. Examination Survey. Serum 25-hydroxyvitamin D, diabetes, and. ethnicity in the Third National Health and Nutrition Examination. Survey. Diabetes Care 2004; 27: 2813-8.
68. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D. and calcium in type 2 diabetes. A systematic review and metaanalysis. J Clin Endocrinol Metab 2007; 92: 2017-29.
69. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium. intake in relation to type 2 diabetes in women. Diabetes Care 2006;. 29: 650-6.
70. Lee S, Clark SA, Gill RK, Christakos S. 1,25-Dihydroxyvitamin. D3 and pancreatic beta-cell function: vitamin D receptors, gene expression,. and insulin secretion. Endocrinology 1994; 134: 1602-10.
71. Bland R, Markovic D, Hills CE, et al. Expression of 25-. hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid. Biochem Mol Biol 2004; 89-90: 121-5.
72. De Boland AR, Norman AW., Influx of extracellular calcium mediates. 1,25-dihydroxyvitamin D3-dependent transcaltachia (the rapid. stimulation of duodenal Ca2+ transport). Endocrinology 1990; 127:. 2475-80.
73. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10: 185-97.
74. Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S. Expression of calbindin-D(28k) in a pancreatic islet. beta-cell line protects against cytokine-induced apoptosis and necrosis. Endocrinology 2001; 142: 3649-55.
75. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus:. state of the art. Trends Endocrinol Metab 2005; 16: 261-6.
76. The EURODIAB Substudy 2 Study Group. Vitamin D supplement. in early childhood and risk for type I (insulindependent) diabetes. mellitus. Diabetologia 1999; 42: 51-4.
77. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort. study. Lancet 2001; 358: 1500-3.
78. Daneman D. Type 1 diabetes. Lancet 2006; 367: 847-58.
79. Pani MA, Knapp M, Donner H, et al. Vitamin D receptor allele. combinations influence genetic susceptibility to type 1 diabetes in. Germans. Diabetes 2000; 49: 504-7.
80. Panierakis C, Goulielmos G, Mamoulakis D, Petraki E,. Papavasiliou E, Galanakis E. Vitamin D receptor gene polymorphisms. and susceptibility to type 1 diabetes in Crete, Greece. Clin. Immunol 2009; 133: 276-81.
81. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms. and diseases. Clin Chim Acta 2006; 371: 1-12.
82. Lemos MC, Fagulha A, Coutinho E, et al. Lack of association of. vitamin D receptor gene polymorphisms with susceptibility to type. 1 diabetes mellitus in the Portuguese population. Hum Immunol. 2008; 69: 134-8.
83. Grimes DS, Hindle E, Dyer T. Sunlight, cholesterol and coronary. heart disease. QJM 1996; 89: 579-89.
84. [84] Carbone LD, Rosenberg EW, Tolley EA. 25-Hydroxyvitamin. D, cholesterol, and ultraviolet irradiation. Metabolism 2008; 57:. 741-8.
85. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA,. Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is associated. with the metabolic syndrome in morbid obesity. Clin Nutr. 2007; 26: 573-80.
86. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk. factors and the serum levels of 25-hydroxyvitamin D in the United. States: data from the Third National Health and Nutrition Examination. Survey. Arch Intern Med 2007; 167: 1159-65.
87. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin. D and 1,25-dihydroxyvitamin D after rosuvastatin. treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs. Ther 2009; 23: 295-9.
88. Pérez-Castrillón JL, Vega G, Abad L, et al. Effects of atorvastatin. on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99: 903-5.
89. [89] Wilczek H, Sobra J, Justova V. Latropathogenic effect of. mevacor on vitamin D metabolism. Cas Lek Cesk 1989; 128: 1254-6.
90. Wilzcek H, Sobra J, Ceska R, et al. Monitoring plasma levels of. vitamin D metabolites in simvastatin therapy in patients with familial. hypercholesterolemia. Cas Lek Cesk 1994; 133: 727-9.
91. Montagnani M, Loré F, Di Cairano G, et al. Effects of pravastatin. treatment on vitamin D metabolites. Clin Ther 1994; 16: 824-9.
92. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum. vitamin D and the metabolic syndrome among U.S. adults. Diabetes. Care 2005; 28: 1228-30.
93. [93] Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary. calcium, vitamin D, and the prevalence of metabolic syndrome. in middle-aged and older U.S. women. Diabetes Care 2005; 28:. 2926-32.
94. Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic. disorders: Systematic review and meta-analysis. Maturitas 2010; 65: 225-36.
95. Procopio M, Borretta G. Vitamin D, parathyroid hormone levels,. and the prevalence of metabolic syndrome in community-dwelling. older adults. J Endocrinol Invest 2003; 26: 1136-42.
96. Reis JP, von Mühlen D, Kritz-Silverstein D, Wingard DL, Barrett-. Connor E. Vitamin D, parathyroid hormone levels, and the prevalence. of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549-55.
97. Hjelmesaeth J, Hofsø D, Aasheim ET, et al. Parathyroid hormone,. but not vitamin D, is associated with the metabolic syndrome in. morbidly obese women and men: a cross-sectional study. Cardiovasc. Diabetol 2009; 8: 7.
98. Reis JP, von Mühlen D, Miller ER. Relation of 25-. hydroxyvitamin D and parathyroid hormone levels with metabolic. syndrome among US adults. Eur J Endocrinol 2008; 159: 41-8.
99. Lee DM, Rutter MK, O'Neill TW, et al.; European Male Ageing. Study Group. Vitamin D, parathyroid hormone and the metabolic. syndrome in middle-aged and older European men. Eur J Endocrinol. 2009; 161: 947-54.
100. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin. D levels are inversely correlated with coronary calcification. Circulation. 1997; 96: 1755-60.
101. Reis JP, von Mühlen D, Michos ED, et al. Serum vitamin D, parathyroid. hormone levels, and carotid atherosclerosis. Atherosclerosis. 2009; 207: 585-90.
102. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction. of clinical cardiovascular events with carotid intima-media. thickness: a systematic review and meta-analysis. Circulation 2007;. 115: 459-67.
103. Targher G, Bertolini L, Padovani R, et al. Serum 25-. hydroxyvitamin D3 concentrations and carotid artery intima-media. thickness among type 2 diabetic patients. Clin Endocrinol (Oxf). 2006; 65: 593-7.
104. [104] London GM, Guérin AP, Verbeke FH. Mineral metabolism. and arterial functions in end-stage renal disease: potential role of. 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-. 20.
105. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2. diabetes mellitus and low vitamin D levels. Diabet Med 2008; 25:. 320-5.
106. Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of. 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth. muscle cells in vitro. Calcif Tissue Int 1987; 41: 112-4.
107. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxyvitamin. D3 and rat vascular smooth muscle cell growth. Hypertension. 1989; 13: 954-9.
108. Ortlepp JR, Hoffmann R, Ohme F, Lauscher J, Bleckmann F, Hanrath. P. The vitamin D receptor genotype predisposes to the development. of calcific aortic valve stenosis. Heart 2001; 85: 635-8.
109. Van Schooten FJ, Hirvonen A, Maas LM, et al. Putative susceptibility. markers of coronary artery disease: association between VDR. genotype, smoking, and aromatic DNA adduct levels in human. right atrial tissue. FASEB J 1998; 12: 1409-17.
110. Ortlepp JR, von Korff A, Hanrath P, Zerres K, Hoffmann R. Vitamin. D receptor gene polymorphism BsmI is not associated with the. prevalence and severity of CAD in a large-scale angiographic cohort. of 3441 patients. Eur J Clin Invest 2003; 33: 106-9.
111. Somjen D, Weisman Y, Kohen F. 25-Hydroxyvitamin D3-. 1alphahydroxylase is expressed in human vascular smooth muscle. cells and is upregulated by parathyroid hormone and estrogenic. compounds. Circulation 2005; 111: 1666-71.
112. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The antiinflammatory. activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 2007; 103: 558-62.
113. Wakasugi M, Noguchi T, Inoue M, et al. Vitamin D3 stimulates the. production of prostacyclin by vascular smooth muscle cells. Prostaglandins. 1991; 42: 127-36.
114. Shea MK, Booth SL, Massaro JM, et al. Vitamin K and vitamin D. status: associations with inflammatory markers in the Framingham. Offspring Study. Am J Epidemiol 2008; 167: 313-20.
115. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the. expression of plasminogen activator inhibitor-1, thrombospondin-1. and thrombomodulin in human aortic smooth muscle cells. J Vasc. Res 2007; 44: 11-8.
116. Oh J, Weng S, Felton SK. 1,25(OH)2 vitamin d inhibits foam. cell formation and suppresses macrophage cholesterol uptake in patients. with type 2 diabetes mellitus. Circulation 2009; 120: 687-98.
117. Autier P, Gandini S. Vitamin D supplementation and total mortality:. a meta-analysis of randomized controlled trials. Arch Intern. Med 2007; 167: 1730-7.
118. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular. mortality in oral 1a-hydroxy vitamin D3 users in a haemodialysis. population. Nephrol Dial Transplant 2004; 19: 179-84.
119. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency. and replacement on endothelial function in asymptomatic. subjects. J Clin Endocrinol Metab 2009; 94: 4023-30.
120. Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac. hypertrophy and QT dispersion in secondary hyperparathyroidism. on hemodialysis. Nephron Clin Pract 2006; 102: c21-9.
121. Sugiura S, Inaguma D, Kitagawa A. Administration of alfacalcidol. for patients with predialysis chronic kidney disease may. reduce cardiovascular disease events. Clin Exp Nephrol 2010;. 14(1): 43-50.
122. Neuhouser ML, Wassertheil-Smoller S, Thomson C. Multivitamin. use and risk of cancer and cardiovascular disease in the. Women's Health Initiative cohorts. Arch Intern Med 2009; 169:. 294-304.
123. Hsia J, Heiss G, Ren H, et al.; Women's Health Initiative Investigators. Calcium/vitamin D supplementation and cardiovascular. events. Circulation 2007; 115: 846-54.
124. Al-Delaimy WK, Rimm E, Willett WC, Stampfer MJ, Hu FB. A. prospective study of calcium intake from diet and supplements and. risk of ischemic heart disease among men. Am J Clin Nutr 2003;. 77: 814-8.
125. Borges AC, Feres T, Vianna LM, Paiva TB. Effect of cholecalciferol. treatment on the relaxant responses of spontaneously hypertensive. rat arteries to acetylcholine. Hypertension 1999; 34: 897-901.
126. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects. of a short-term vitamin D(3) and calcium supplementation on. blood pressure and parathyroid hormone levels in elderly women. J. Clin Endocrinol Metab 2001; 86: 1633-7.
127. Sowers MR, Wallace RB, Lemke JH. The association of intakes of. vitamin D and calcium with blood pressure among women. Am J. Clin Nutr 1985; 42: 135-42.
128. [128] Lind L, Wengle B, Wide L, Ljunghall S. Reduction of blood pressure. during long-term treatment with active vitamin D (alphacalcidol). is dependent on plasma renin activity and calcium status. A. double-blind, placebo-controlled study. Am J Hypertens 1989; 2:. 20-5.
129. Margolis KL, Ray RM, Van Horn L, et al.; Women's Health Initiative. Investigators. Effect of calcium and vitamin D supplementation. on blood pressure: the Women's Health Initiative Randomized. Trial. Hypertension 2008; 52: 847-55.
130. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ,. Curhan GC. Vitamin D intake and risk of incident hypertension: results. from three large prospective cohort studies. Hypertension. 2005; 46; 676-82.
131. Jorde R, Bonaa KH. Calcium from dairy products, vitamin D intake,. and blood pressure: the Tromso Study. Am J Clin Nutr 2000;. 71: 1530-5.
132. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of. calcium and vitamin D supplementation on blood glucose and. markers of inflammation in nondiabetic adults. Diabetes Care. 2007; 30: 980-6.
133. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation. reduces insulin resistance in South Asian women living in New. Zealand who are insulin resistant and vitamin D deficient a randomised,. placebo-controlled trial. Br J Nutr 2010; 103: 549-55.
134. Avenell A, Cook JA, MacLennan GS, McPherson GC. RECORD. trial group. Vitamin D supplementation and type 2 diabetes: a. substudy of a randomised placebo-controlled trial in older people. (RECORD trial, ISRCTN 51647438). Age Ageing 2009; 38: 606-9.
135. de Boer IH, Tinker LF, Connelly S, et al.; For the Women's Health. Initiative Investigators. Calcium plus vitamin D supplementation. and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008; 31: 701-7.
136. Bonakdaran S, Ayatollahi H, Mojahedi MJ, Sharifipoor F, Shakeri. M. Impact of treatment with oral calcitriol on glucose intolerance. and dyslipidemia(s) in hemodialysis patients. Saudi J Kidney Dis. Transpl 2008; 19: 942-7.
137. Caan B, Neuhouser M, Aragaki A, et al. Calcium plus vitamin D. supplementation and the risk of postmenopausal weight gain. Arch. Intern Med 2007; 167: 893-902.
138. Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation. with calcium + vitamin D enhances the beneficial effect. of weight loss on plasma lipid and lipoprotein concentrations. Am J. Clin Nutr 2007; 85: 54-9.
139. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation. enhances the beneficial effects of weight loss on cardiovascular. disease risk markers. Am J Clin Nutr 2009; 89: 1321-7.
140. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D. supplementation. Osteoporos Int 2009 Dec 3 [Epub ahead of print].